Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Trilochan Sahoo, Allan Provonost, Peter Lea


Trilochan Sahoo is CombiMatrix's new director of cytogenetics. Sahoo joins the Irvine, Calif.-based molecular testing services firm from Quest Diagnostics Nichols Institute, where he was senior director of cytogenetics. He also served as laboratory director at Signature Genomics. His expertise is in the "development, evaluation and implementation of microarray-based technologies, especially as used as an important diagnostic tool in clinical cytogenetics and genomics," the company said in a statement.

SQI Diagnostics has appointed Allan Pronovost to its board of directors. He will also act as strategic advisor to Toronto-based SQI, assisting the company in its efforts to secure strategic partnerships and additional capital, SQI said.

Pronovost is currently the president and chief scientific officer of Red Lion Chem Tech, a San Diego-based consortium of health related companies. He is also CEO of Stone Investments, an investment holding company. Provonost held other top-level management positions at Quest Diagnostics, BioAlliances Group, and Quidel.

He replaces Peter Lea who has resigned from SQI's board. Lea, who founded SQI 15 years ago and invented its multiplex array technology, will continue as an active, non-voting senior advisor to the board, SQI said.